The Annual General Meeting 2026 will take place on Thursday, March 19, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark.
Genmab will hold a conference call to discuss its 2025 financial results at 6:00 pm CET, 5:00 pm GMT or 12:00 pm EST on February 17, 2026
Genmab hosted its 2025 R&D Update and ASH Data Review virtually on Thursday, December 11, 2025.
This meeting was not an official program of the ASH Annual Meeting.
Fireside Chat with Chief Executive Officer, Jan van de Winkel, and Chief Financial Officer, Anthony Pagano.
Fireside Chat with Chief Executive Officer Jan van de Winkel and Chief Financial Officer Anthony Pagano.
On August 7, Genmab announced its financial results for the first half of 2025.
On Monday, June 2 Genmab hosted a Post-ASCO R&D update with a focus on recent Rina-S data.
This was not an official event of the ASCO Annual Meeting.
On May 8, Genmab announced its financial results for the first quarter of 2025.
The Annual General Meeting 2025 took place on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark.
On February 12, Genmab announced its full-year financial results for 2024.
Genmab hosted its 2024 R&D Update and ASH Data Review virtually on Wednesday, December 11, 2024.
This meeting was not an official program of the ASH Annual Meeting.
Fireside Chat with Chief Financial Officer Anthony Pagano.
On November 6, Genmab announced its financial results for the first nine months of 2024.
On August 8, Genmab announced its financial results for the first six months of 2024.
On Monday, June 3 Genmab held a review of data presented at ASCO from its mid- to late-stage pipeline.
This meeting was not an official program of the ASCO Annual Meeting.